Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nicotinamide protects against diet-induced body weight gain, increases energy expenditure, and induces white adipose tissue beiging

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Rodríguez-Millán, Elisabeth
  • Sebastián, David|||0000-0002-7260-3869
  • Blanco-Soto, Rosi
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Mato, Eugènia|||0000-0001-8121-9335
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Roglans, Núria
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Villena, Josep A.|||0000-0002-2200-2985
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Scope: Interventions that boost NAD+ availability are of potential therapeutic interest for obesity treatment. The potential of nicotinamide (NAM), the amide form of vitamin B3 and a physiological precursor of nicotinamide adenine dinucleotide (NAD)+, in preventing weight gain has not previously been studied in vivo. Other NAD+ precursors have been shown to decrease weight gain; however, their impact on adipose tissue is not addressed. Methods and results: Two doses of NAM (high dose: 1% and low dose: 0.25%) are given by drinking water to C57BL/6J male mice, starting at the same time as the high-fat diet feeding. NAM supplementation protects against diet-induced obesity by augmenting global body energy expenditure in C57BL/6J male mice. The manipulation markedly alters adipose morphology and metabolism, particularly in inguinal (i) white adipose tissue (iWAT). An increased number of brown and beige adipocyte clusters, protein abundance of uncoupling protein 1 (UCP1), mitochondrial activity, adipose NAD+, and phosphorylated AMP-activated protein kinase (P-AMPK) levels are observed in the iWAT of treated mice. Notably, a significant improvement in hepatic steatosis, inflammation, and glucose tolerance is also observed in NAM high-dose treated mice. Conclusion: NAM influences whole-body energy expenditure by driving changes in the adipose phenotype. Thus, NAM is an attractive potential treatment for preventing obesity and associated complications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

FTY720-P, a Biased S1PR Ligand, Increases Mitochondrial Function through STAT3 Activation in Cardiac Cells

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The double burden, type 1 diabetes and heart failure-a comprehensive review

  • Julián, María Teresa|||0000-0003-2524-1823
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading to more hospitalizations and increased case fatality rates. Several risk factors contribute to HF in T1D, including poor glycemic control, female gender, smoking, hypertension, elevated BMI, and albuminuria. However, early and intensive glycemic control can mitigate the long-term risk of HF in individuals with T1D. The pathophysiology of diabetes-associated HF is complex and multifactorial, and the underlying mechanisms in T1D remain incompletely elucidated. In terms of treatment, much of the evidence comes from type 2 diabetes (T2D) populations, so applying it to T1D requires caution. Sodium-glucose cotransporter 2 inhibitors have shown benefits in HF outcomes, even in non-diabetic populations. However, most of the information about HF and the evidence from cardiovascular safety trials related to glucose lowering medications refer to T2D. Glycemic control is key, but the link between hypoglycemia and HF hospitalization risk requires further study. Glycemic variability, common in T1D, is an independent HF risk factor. Technological advances offer the potential to improve glycemic control, including glycemic variability, and may play a role in preventing HF. In summary, HF in T1D is a complex challenge with unique dimensions. This review focuses on HF in individuals with T1D, exploring its epidemiology, risk factors, pathophysiology, diagnosis and treatment, which is crucial for developing tailored prevention and management strategies for this population.